Gedeon Richter Signs an Asset Purchase Agreement with Mycenax for Biosimilar Tocilizumab to Treat Rheumatoid Arthritis
Shots:
- Mycenax to get $5M upfront and will get $16.5M as total deal value in four installments. Richter to get exclusive WW rights to develop- manufacture and commercialize biosimilar tocilizumab
- The focus of the agreement is to bolster its rheumatology portfolio with addition of Mycenax’s candidate. The biosimilar tocilizumab assets comprise the cell lines- intellectual property (IP) rights- technology know-how also the data generated by Mycenax
- Tocilizumab is an investigational product formulated as subcutaneous and intravenous formulations targeted for RA with expected commercialization in EU- Canada- Australia and Japan in 2025 and is approved for paediatric juvenile idiopathic arthritis- systemic juvenile idiopathic arthritis- giant cell arteritis and CAR-T cell-induced cytokine release syndrome
Click here to read full press release/ article | Ref: Gedeon Richter | Image: Behance
Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com
